ArticleOncoTargets and therapy2010
Current and emerging therapies for the treatment of pancreatic cancer.
Article in OncoTargets and therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Radiofrequency ablation for unresectable locally advanced pancreatic cancer: a systematic review.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2014Pooled it
- Pooled it
- A prospective study of patient reported outcomes in pancreatic and peri-ampullary malignancy.World journal of surgery · 2013Trial
- Development and validation of a competing risk model for second primary pancreatic ductal adenocarcinoma: A population-based study.Frontiers in surgery · 2022Article
- Impact of time interval between multidisciplinary team meeting and intended pancreatoduodenectomy on oncological outcomes.BJS open · 2020Article
- Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.Radiation oncology (London, England) · 2020Article
- The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic.Expert review of anticancer therapy · 2018Review
- Irreversible Electroporation of the Pancreas Using Parallel Plate Electrodes in a Porcine Model: A Feasibility Study.PloS one · 2017Article
- Article
- Review of endoscopic radiofrequency in biliopancreatic tumours with emphasis on clinical benefits, controversies and safety.World journal of gastroenterology · 2016Review
- Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Article
- Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.Cell death & disease · 2015Article
- Personalized virotherapy in cancer.Aging · 2015Article
- Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase.OncoTargets and therapy · 2015Article
- Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.Cell death discovery · 2015Article
- Antimetabolite Treatment for Pancreatic Cancer.Chemotherapy · 2014Article
- Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.Cancer gene therapy · 2013Article
- Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature.Oncology letters · 2013Article
- In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens.Molecular cancer · 2012Article
- A 1536-well quantitative high-throughput screen to identify compounds targeting cancer stem cells.Journal of biomolecular screening · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic adenocarcinoma carries a dismal prognosis and remains a significant cause of cancer morbidity and mortality. Most patients survive less than 1 year; chemotherapeutic options prolong life minimally. The best chance for long-term survival is complete resection, which offers a 3-year survival of only 15%. Most patients who do undergo resection will go on to die of their disease. Research in chemotherapy for metastatic disease has made only modest progress and the standard of care remains the purine analog gemcitabine. For resectable pancreatic cancer, presumed micrometastases provide the rationale for adjuvant chemotherapy and chemoradiation (CRT) to supplement surgical management. Numerous randomized control trials, none definitive, of adjuvant chemotherapy and CRT have been conducted and are summarized in this review, along with recent developments in how unresectable disease can be subcategorized according to the potential for eventual curative resection. This review will also emphasize palliative care and discuss some avenues of research that show early promise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.